We are very proud at LEO Pharma that, as well as our firmly established therapy areas of Dermatology (skin) and Thrombosis (blood clots), we most recently established a new BioDermatology division following the announcement of an exciting new strategic partnership with Astra Zeneca in July 2016. This marks the entry by LEO Pharma into developing innovative new biologic therapies for skin conditions, firstly psoriasis and atopic dermatitis.
Building on our long-established heritage and expertise in topical treatments (those applied to the skin), the new BioDermatology division offers the opportunity for new and current colleagues to play a key part at the start of this exciting journey. By the end of 2017, LEO Pharma aims to be in the unique position of providing products and resources for people living with psoriasis across the entire disease severity spectrum, in both primary and secondary care, including pharmacies. This represents the key next step in our growth journey.
Our entry into biologics provides great opportunities for personal development for our current team to build on their skills and knowledge-base, as well as offering new roles for people who may want to join us on this exciting journey. We are investing in our commitment not only to patients and our people but to the health professionals who care for them and those who design and shape dermatology service provision.
Our commitment to transparency and a genuine patient focus remains the focal point of our culture and business decisions. We are delighted to enter this new chapter in our journey and are excited to grow and develop our team in the process.
To learn more about opportunities in the team visit our Vacancies page
Cookies on this site